Home >Companies >Cipla ties up with Serum Institute of India to distribute vaccines in Europe

Mumbai: India’s second largest generic drug maker Cipla Ltd on Thursday announced that its subsidiary Cipla Europe NV has entered into a distribution agreement with Serum Institute of India Ltd (SII) for marketing the latter’s paediatric vaccines in the European market.

Under the agreement, SII will develop and manufacture paediatric vaccines and Cipla Europe will seek approval from the European Medicines Agency and market the products in Europe, the firm said in a BSE filing.

The collaboration with SII will enable Cipla Europe’s entry into the vaccines segment, the firm said.

“We see vaccines as one of the critical components of our offering to European patients. With Cipla’s front-end presence and with the support of a dedicated sales force, we will broaden the reach of vaccines across Europe," said Frank Pieters, head of Europe, Cipla.

Over the last six months, Cipla has increased its presence in Europe by launching respiratory products such as Salmeterol/Fluticasone in various countries such as Germany, Sweden, Czech Republic, Slovakia and Croatia, the firm said. In July, it entered into an exclusive partnership with BioQuiddity Inc. to market a drug with anaesthetic applications for post-surgical pain management.

At 11:41am, Cipla’s shares were trading at 607.10, up 1.31%, on BSE, while the benchmark Sensex was trading flat at 28,023.41 points, down by just 0.03%.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our App Now!!

Edit Profile
My ReadsRedeem a Gift CardLogout